Perlmutter named CEO of Eikon, a biotech with $148M to apply Nobel-winning tech to undruggable targets ChemoCentryx's stock sinks as FDA flags issues with pivotal data Adagio's COVID-19 antibody marches on to phase 2/3 after early data suggest 12 months of protection Sponsored: Mitotech brings novel approach to treating eye disorders Childhood-cancer-focused Day One banks $130M for pan-RAF inhibitor Sponsored: Risk Mitigation in Direct-to-Patient Clinical Trials Jaguar snags a CMO after banking $139M to propel its preclinical gene therapies Esker Therapeutics launches with $70M and a focused approach for autoimmune diseases beyond JAKs NIH-backed device is first to offer long-term wireless monitoring of Parkinson's patients' brain activity Expelling cancer by squeezing out rogue cells Featured Story | By Nick Paul Taylor Roger Perlmutter has taken up the CEO post at Eikon Therapeutics. The startup disclosed the hiring of the former president of Merck Research Laboratories alongside news that it has raised a $148 million series A round to apply live-cell super-resolution microscopy to drug discovery. read more |
| |
|---|
|
Top Stories By Nick Paul Taylor ChemoCentryx’s stock price almost halved after the FDA raised concerns with a filing for approval of avacopan. The agency raised multiple concerns with ChemoCentryx’s phase 3 clinical trial ahead of an advisory committee meeting to discuss the complement 5a receptor inhibitor this week. read more By Annalee Armstrong Adagio Therapeutics’ COVID-19 antibody drug could provide as much as 12 months of protection against infection with the coronavirus, according to an early-stage clinical trial, supporting advancement of the therapy to phase 2/3. read more Sponsored By: Mitotech S.A. Mitotech focuses its clinical development efforts on ophthalmology, hoping to deliver its mitochondria targeted therapies to patients suffering from age-related as well as rare genetic eye diseases. read more By Amirah Al Idrus It’s been a busy year for Day One Biopharmaceuticals. Just nine months after debuting with $60 million to tackle childhood cancers, the company is topping up its coffers with a $130 million series B financing. The funds will bankroll development and launch plans for its lead program as well as its search for new drug programs to pick up. read more Sponsored By: Catalent Clinical Supply The COVID-19 pandemic has made society very aware of the need to be flexible in the approach to daily life. Use and acceptance of DTP has grown due to the pandemic, and sponsors quickly began to rethink their Direct-to-Patient (DTP) approach as patients increasingly requested that their study drugs be shipped to their homes. read more By Amirah Al Idrus Jaguar Gene Therapy emerged in February with about $40 million from Deerfield Management and a plan to get its leading assets into the clinic in the next couple of years. Now, having raised another $139 million to fuel that mission, the company is adding a chief medical officer to its team. read more By Ben Adams There’s a new autoimmune disease player in town: Esker Therapeutics has raised $70 million to work on a new, focused way that can go beyond some of the limitations of JAK1 drugs. read more By Andrea Park In a veritable whirlwind of neurological discovery—a brain storm, if you will—researchers have developed a device with the potential to massively improve our understanding of the effects of Parkinson’s disease on brain activity. read more By Angus Liu Cancer cells multiply out of control because they're able to escape a mechanism known as programed cell death. But scientists at the Massachusetts Institute of Technology and King’s College London have uncovered key functions of another pathway that the body can use to dispose those rogue cells. That mechanism, called "cell extrusion" could inspire new methods for stopping cancer. read more Resources Sponsored By: Veeva Learn how to develop a standards program that has your full team’s buy-in and improves the efficiency and quality of your clinical trials. Sponsored By: ClearView Healthcare Partners As clinical treatment options become more patient-centric, digital therapeutics provide forward-looking biopharma players the opportunity to augment the value of their offerings to stakeholders. Sponsored By: Veeva One top 10 pharma outlines three key steps to launching a modular content strategy to generate localized content faster. Sponsored By: Blue Matter This 77-page e-book explores 7 keys to success that any biopharma company needs to keep in mind as it enters Europe. Sponsored by: Datacubed Health The average clinical trial spends $40,000 per patient. Yet despite these high costs, most trials struggle to retain patients. Sponsored By: AmerisourceBergen Developing a quality product and getting it approved for distribution is not enough to guarantee commercial success. Sponsored By: WCG Trifecta The new standards in study training help sponsors and CROs reduce costs by 60%, cut training time by 50%, and start enrollment 55 days faster – learn more today. Sponsored By: Oracle Health Sciences New research indicates an accelerated adoption of decentralized clinical trials due to COVID-19. Sponsored by: Cytiva A one-stop hub for Cytiva resources to support process intesification Sponsored By: August Bioservices How has COVID-19 impacted CRO/CDMO customer (dis)satisfaction and outsourcing decisions for pharma and biotech companies in 2021 and beyond? Sponsored by: Cytiva A one-stop hub for Cytiva resources to support process development and manufacturing of your novel molecule Sponsored By: Within3 We enable virtual work — offering over-time sessions where participants are more focused, insights are more diverse and business goals are met. Sponsored by: TAC Roche has inked a $1.8 billion, all-cash deal for GenMark Diagnostics, to acquire its molecular tests designed to screen patient samples for multiple infections simultaneously. Sponsored By: Remarque Systems Remarque Systems consolidates data, then layers on visualization and automated metrics to generate consistent, actionable data insights in real-time. Click here for more info. Sponsored By: Culture Biosciences Find out how upstream bioprocess scientists can use Culture Biosciences’ bioreactor system and real-time data visualizations to get faster insights and get their product to market more quickly. Sponsored By: BC Platforms Those wishing to unlock RWD’s true value must have access to a variety of data sources/types and the technological capabilities to use the data to uncover meaningful insights. Sponsored By: Oracle Health Sciences New research indicates an accelerated adoption of decentralized clinical trials due to COVID-19. Sponsored by: Catalent Autologous cell therapies have seen propelled growth since 2017, with the spotlight on the first FDA approval of a chimeric antigen receptor (CAR) T cell immunotherapy, Kymriah® (tisagenlecleucel), for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia. Sponsored by: Catalent Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase. Sponsored by: Catalent Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent. Sponsored by: Catalent In a BioPharma Dive industry survey, planning and forecasting were identified as top concerns for trial sponsors. In response to this need, the CSM team at Catalent has developed a methodology for identifying, evaluating, and proactively managing the inherent risks involved in clinical trial supply chain management. Sponsored by: Catalent Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study. Drug Development Boot Camp® 2021 Onsite and VIRTUAL in real time November 17-18, 2021 | Register now! Pre-Boot Camp preparation is now available. Medical Affairs Strategic Summit (MASS) Virtual May 5-7, 2021 | Virtual Event TMF Virtual Summit May 18-20, 2021 | Virtual Event Vaccines, cell and gene therapy, therapeutic antibodies and RNA drugs May 20-21, 2021 | 12 p.m. EST / 9 a.m. PST Vaccines, cell and gene therapy, antibodies, and RNA-based drugs June 10-11, 2021 | 9 a.m. EST / 6 a.m. PST Biopharma Supply Chain June 29-30, 2021 | Virtual Event | 